• Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported sales of 22,575 common shares on May 11-13, leaving 63,443 shares owned.
• Sales were executed at weighted-average prices of USD 29.71, USD 29.36, USD 28.58.
• Filing also showed option exercises totaling 16,226 shares at prices ranging from USD 1.08 to USD 16.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001672659-26-000027), on May 13, 2026, and is solely responsible for the information contained therein.